DNTH

82.6302.59%
AF

Alison F. Lawton

Independent Chairman of the Board

Ms. Alison F. Lawton serves as Director of Dianthus Therapeutics, Inc December 2020 and serves as its Chairman of the Board. She is Director of BlueRock Therapeutics LP. She serves as Independent Director of SwanBio Therapeutics, Inc. since January 2021. She serves as Independent Chairman at Magenta Therapeutics, Inc. since August 4, 2021. She serves as Member of Strategic Advisory Board at Hybridize Therapeutics B.V. She serves as Director at AgBiome, LLC since May 4, 2021. She was Independent Director of Spyre Therapeutics, Inc. (formerly known as Aeglea BioTherapeutics, Inc.) from December 15, 2020 to February 01, 2024. She was employed at Spyre Therapeutics, Inc. from December 15, 2020 to February 01, 2024. Ms. Lawton was a Director of Kaleido BioSciences, Inc. since August 2018 until October 2020. She serves as an Independent Director at Magenta Therapeutics, Inc. since December 22, 2020. She had been Independent Director of X4 Pharmaceuticals, Inc. since October 5, 2020 until June 9, 2025. She served as Member of Corporate Advisory Board at X4 Pharmaceuticals Inc. since April 4, 2016. She was Special Advisor for Office of the Chief Executive Officer at Kaleido Biosciences, Inc since June 2020 until December 2020. Ms. Lawton initially joined the Kaleido BioSciences as Chief Operating Officer and President from December 2017 to August 2018. She served as a consultant to Aura from March 2014 to December 2014. Ms. Lawton was Advisor of Aura Biosciences Inc. since December 11, 2017 and served as the Chief Operating Officer since January 2015 until December 11, 2017. Ms. Lawton served as Board Advisor of Magenta Therapeutics, Inc. since April 6, 2018 until December 2020. Ms. Lawton served as Chief Operating Officer at OvaScience Inc., a life sciences company, from January 2013 to January 2014. Ms. Lawton is a Corporate Advisor to Visgo Therapeutics. In addition, from 2014 to 2017, Ms. Lawton served as a biotech consultant for various companies including Chief Operating Officer of X4 Pharmaceuticals Inc., until June 13, 2016. She global pharmaceutical and biotechnology experience, at Sanofi Genzyme and in the U.K. at Warner-Lambert/Parke-Davis. Ms. Lawton spent two decades of her career at Genzyme, serving in senior management roles during its growth from a small US company to a global commercial organization with over 10,000 employees. She served as Head of Genzyme Biosurgery, where she was responsible for its global cell therapy, regenerative medicine, orthopedics and surgical businesses; and head of Global Market Access, with responsibility for regulatory affairs, global health outcomes and strategic pricing, global public policy and global product safety. Ms. Lawton served as General Manager of the Biosurgery business of Sanofi Genzyme since May 2010 and served as its Senior Vice President. She was responsible for Genzyme's global orthopedics, biosurgical specialty (BSS) and cell therapy and regenerative medicine (CT&RM) businesses. She served as Senior Vice President and General Manager of the Sanofi Biosurgery Business Unit, where she was responsible for three separate franchises, including surgical, cell therapy and regenerative medicine and orthopedics. She served as Senior Vice President of Global Market Access for Genzyme, where she led global functional organizations, including regulatory affairs and quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. Ms. Lawton led global functional organizations, including regulatory affairs and quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. She served as Senior Vice President of Regulatory Affairs and Corporate Quality Systems at Sanofi Genzyme (Formerly, Genzyme Corporation). She served as Senior Vice President of Regulatory Affairs and Corporate Quality Systems at Genzyme Oncology, Inc. (alternate name, Genzyme Molecular Oncology), a division of Sanofi Genzyme. She joined Sanofi Genzyme in 1991. Ms. Lawton has held various positions in Genzyme's regulatory affairs department since she began with Sanofi Genzyme, as an international regulatory affairs specialist. She was responsible for all of Genzyme's global regulatory activities and leads Sanofi Genzyme's corporate quality systems organization. Ms. Lawton began her career at Warner-Lambert/Parke-Davis, where she held several increasingly senior regulatory affairs positions. Prior to Genzyme, she worked at Warner-Lambert, where she gained experience in both regulatory affairs and marketing. Ms. Lawton worked in the UK at Parke-Davis. She served as an Independent Director of Verastem, Inc. since November 26, 2012 until May 19, 2020. She serves as a Director of MassMEDIC, SwanBio and Follica, Inc. She was an Independent Non-Executive Director at ProQR Therapeutics N.V. since May 2024 until 2026 and served as its Independent Member of the Supervisory Board since September 17, 2014. She served as a Director of Magenta Therapeutics, Inc. from May 2017 to March 2018. She serves on the Scientific Advisory Board for the Massachusetts Life Science Center. She served as a Director of CoLucid Pharmaceuticals, Inc., since March 15, 2016 until March 1, 2017. She served as a Director of Cubist Pharmaceuticals Inc. from February 16, 2012 to January 2015. She served two terms as the industry representative on the U.S. Food and Drug Administration (FDA) Cell & Gene Therapy Advisory Panel. She served as Chief Executive Officer of Kaleido BioSciences, Inc. since August 2018 until June 16, 2020 and served as its President since December 2017 until June 16, 2020. She has extensive experience leading and operating biotech and pharmaceutical companies. She was President and Chair of the Board of Regulatory Affairs Professional Society. Ms. Lawton has a B.Sc. Hons. Degree in Pharmacology from King's College, University of London.

Positions